{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:12:52Z","timestamp":1773889972114,"version":"3.50.1"},"reference-count":16,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Efmoroctocog alfa (ELOCTATE) and rurioctocog alfa pegol (ADYNOVATE) are extended half-life (EHL) recombinant human coagulation factor VIII (rFVIII) products indicated for the prophylaxis of bleeding and in the perioperative setting in patients with hemophilia A. Continuous infusion (CI) using a standard half-life (SHL) rFVIII is an established alternative to bolus infusion (BI) for surgical procedures or major bleeds and has several advantages over BI, including the ability to maintain stable FVIII levels and cost savings due to reduced product usage. There is no published stability data for efmoroctocog alfa and rurioctocog alfa pegol, and the manufacturers currently recommend the use of rurioctocog alfa pegol via BI within 3\u2009hours of reconstitution and efmoroctocog alfa via BI within 6\u2009hours of reconstitution. The aim of this study was to determine the in vitro stability of efmoroctocog alfa and rurioctocog alfa pegol over a 5-day period. Triplicate samples of efmoroctocog alfa and rurioctocog alfa pegol were tested. After reconstitution, the product was diluted in FVIII-deficient plasma to achieve a baseline FVIII activity of 0.8 to 1.2 U\/mL. Assessment of sample integrity and one-stage FVIII assays were performed on each sample at 0, 3, 6, 12, 24, 48, 72, and 96\u2009hours. The in vitro FVIII did not decrease over the 96\u2009hours following reconstitution. The average FVIII activity for efmoroctocog alfa was 1.03\u2009\u00b1\u20090.17 U\/mL, and the average FVIII activity for rurioctocog alfa pegol was 1.06\u2009\u00b1\u20090.12 U\/mL. Efmoroctocog alfa and rurioctocog alfa pegol demonstrated stability for 96\u2009hours. This suggests that CI would be feasible for these EHL products.<\/jats:p>","DOI":"10.1055\/a-2826-5671","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:43:56Z","timestamp":1773877436000},"source":"Crossref","is-referenced-by-count":0,"title":["In Vitro Stability Study Supports the Use of Efmoroctocog Alfa and Rurioctocog Alfa Pegol for Continuous Infusion in Hemophilia A"],"prefix":"10.1055","author":[{"given":"Gianna","family":"Pastore","sequence":"additional","affiliation":[{"name":"Queensland Haemophilia Centre, Department of Haematology and BMT, Royal Brisbane and Women's Hospital, Herston Queensland, Australia"},{"name":"Pathology Queensland, Central Laboratory, Royal Brisbane and Women's Hospital, Herston, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"De Lepervanche","sequence":"additional","affiliation":[{"name":"Pathology Queensland, Central Laboratory, Royal Brisbane and Women's Hospital, Herston, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-2884","authenticated-orcid":false,"given":"Jane A.","family":"Mason","sequence":"additional","affiliation":[{"name":"Queensland Haemophilia Centre, Department of Haematology and BMT, Royal Brisbane and Women's Hospital, Herston Queensland, Australia"},{"name":"Pathology Queensland, Central Laboratory, Royal Brisbane and Women's Hospital, Herston, Australia"},{"name":"Haematology and Haemophilia Service, Queensland Children's Hospital, South Brisbane, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"S 01","key":"ref1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/21556660.2019.1658327","article-title":"Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy","volume":"8","author":"M McCall","year":"2019","journal-title":"J Drug Assess"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000488060","article-title":"Extended half-life factor VIII and factor IX preparations","volume":"45","author":"L Graf","year":"2018","journal-title":"Transfus Med Hemother"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"P Collins","year":"2016","journal-title":"Haemophilia"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1445-5994.1998.tb02078.x","article-title":"Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience","volume":"28","author":"P J Campbell","year":"1998","journal-title":"Aust N Z J Med"},{"issue":"02","key":"ref5","first-page":"217","article-title":"Surgical evaluation of a recombinant factor VIII prepared using a plasma\/albumin-free method: efficacy and safety of Advate in previously treated patients","volume":"100","author":"C N\u00e9grier","year":"2008","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1365-2141.2000.02226.x","article-title":"Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery","volume":"110","author":"A Batorova","year":"2000","journal-title":"Br J Haematol"},{"issue":"03","key":"ref7","first-page":"203","article-title":"Extended stability and sterility of antihemophilic factor human","volume":"22","author":"S Shields","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2516.2005.01094.x","article-title":"In vitro evaluation of B-domain deleted recombinant factor VIII (ReFacto) stability during simulated continuous infusion administration","volume":"11","author":"E Neidhardt","year":"2005","journal-title":"Haemophilia"},{"issue":"04","key":"ref12","first-page":"e280","article-title":"Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A","volume":"24","author":"I CL Kremer Hovinga","year":"2018","journal-title":"Haemophilia"},{"issue":"01","key":"ref13","first-page":"1","article-title":"Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A","volume":"116","author":"J N Mahlangu","year":"2016","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/hae.13953","article-title":"Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study","volume":"26","author":"B Nolan","year":"2020","journal-title":"Haemophilia"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hae.13807","article-title":"Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: final results of a multicentre, single-arm phase III trial","volume":"25","author":"R Gruppo","year":"2019","journal-title":"Haemophilia"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/01.mbc.0000220236.92219.08","article-title":"Stability of ADVATE, antihemophilic factor (recombinant) plasma\/albumin-free method, during simulated continuous infusion","volume":"17","author":"M Fernandez","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ajh.2830450305","article-title":"Stability of factor VIII concentrates after reconstitution","volume":"45","author":"S Schulman","year":"1994","journal-title":"Am J Hematol"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood.V108.11.4004.4004","article-title":"Stability and sterility of sucrose-formulated recombinant factor VIII (Kogenate FS\/Bayer) for use during continuous infusion","volume":"108","author":"L Regan","year":"2006","journal-title":"Blood"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3324\/haematol.2015.136275","article-title":"A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients","volume":"101","author":"H Hazendonk","year":"2016","journal-title":"Haematologica"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2826-5671.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:43:59Z","timestamp":1773877439000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2826-5671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1055\/a-2826-5671","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}